Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Brief description of study
This research study is studying the combination of Atezolizumab and Bevacizumab as a
possible treatment for Advanced Non-Clear Cell Kidney Cancer.
Clinical Study Identifier: NCT02724878
Detailed Study Description
This research study is a Phase II clinical trial. In this research the investigators are
studying the combination of Atezolizumab with Bevacizumab. Participants will receive both
vascular endothelial targeted therapy and immunotherapy.
The FDA (the U.S. Food and Drug Administration) has not approved Atezolizumab for Advanced
Non-Clear Cell Kidney Cancer, but it has been approved for other uses.
The FDA has approved Bevacizumab with Interferon (IFNa) as a treatment option for Advanced